vs

Side-by-side financial comparison of Galiano Gold Inc. (GAU) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.

Galiano Gold Inc. is the larger business by last-quarter revenue ($166.8M vs $158.6M, roughly 1.1× Stoke Therapeutics, Inc.).

Galiano Gold Inc. is a Canada-based mineral exploration and production firm focused on gold assets. Its core operation is the Asanko Gold Mine in Ghana, West Africa. It extracts, processes and sells gold products to global precious metals markets, catering to both industrial clients and investment sector purchasers.

Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.

GAU vs STOK — Head-to-Head

Bigger by revenue
GAU
GAU
1.1× larger
GAU
$166.8M
$158.6M
STOK

Income Statement — Q3 FY2025 vs Q1 FY2025

Metric
GAU
GAU
STOK
STOK
Revenue
$166.8M
$158.6M
Net Profit
$112.9M
Gross Margin
Operating Margin
24.3%
70.2%
Net Margin
71.2%
Revenue YoY
3661.1%
Net Profit YoY
528.0%
EPS (diluted)
$1.90

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GAU
GAU
STOK
STOK
Q3 25
$166.8M
Q2 25
$95.7M
Q1 25
$31.7M
$158.6M
Q4 24
$22.6M
Q3 24
$71.1M
Q2 24
$64.0M
Q1 24
$31.7M
Q3 23
$239.3M
Net Profit
GAU
GAU
STOK
STOK
Q3 25
Q2 25
$4.1M
Q1 25
$-3.2M
$112.9M
Q4 24
$-10.5M
Q3 24
$1.1M
Q2 24
$8.8M
Q1 24
Q3 23
$19.5M
Operating Margin
GAU
GAU
STOK
STOK
Q3 25
24.3%
Q2 25
18.4%
Q1 25
8.2%
70.2%
Q4 24
-60.4%
Q3 24
Q2 24
Q1 24
17.2%
Q3 23
9.1%
Net Margin
GAU
GAU
STOK
STOK
Q3 25
Q2 25
4.3%
Q1 25
-10.1%
71.2%
Q4 24
-46.4%
Q3 24
1.5%
Q2 24
13.8%
Q1 24
Q3 23
8.2%
EPS (diluted)
GAU
GAU
STOK
STOK
Q3 25
Q2 25
Q1 25
$1.90
Q4 24
$-0.15
Q3 24
Q2 24
Q1 24
Q3 23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GAU
GAU
STOK
STOK
Cash + ST InvestmentsLiquidity on hand
$274.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$350.1M
Total Assets
$406.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GAU
GAU
STOK
STOK
Q3 25
Q2 25
Q1 25
$274.8M
Q4 24
$128.0M
Q3 24
Q2 24
Q1 24
Q3 23
Stockholders' Equity
GAU
GAU
STOK
STOK
Q3 25
Q2 25
Q1 25
$350.1M
Q4 24
$229.0M
Q3 24
Q2 24
Q1 24
Q3 23
Total Assets
GAU
GAU
STOK
STOK
Q3 25
Q2 25
Q1 25
$406.9M
Q4 24
$271.6M
Q3 24
Q2 24
Q1 24
Q3 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GAU
GAU
STOK
STOK
Operating Cash FlowLast quarter
$41.9M
$131.8M
Free Cash FlowOCF − Capex
$131.7M
FCF MarginFCF / Revenue
83.0%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
1.17×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GAU
GAU
STOK
STOK
Q3 25
$41.9M
Q2 25
$17.5M
Q1 25
$13.0M
$131.8M
Q4 24
$-23.2M
Q3 24
$28.6M
Q2 24
$9.2M
Q1 24
Q3 23
Free Cash Flow
GAU
GAU
STOK
STOK
Q3 25
Q2 25
Q1 25
$131.7M
Q4 24
$-23.2M
Q3 24
Q2 24
Q1 24
Q3 23
FCF Margin
GAU
GAU
STOK
STOK
Q3 25
Q2 25
Q1 25
83.0%
Q4 24
-102.7%
Q3 24
Q2 24
Q1 24
Q3 23
Capex Intensity
GAU
GAU
STOK
STOK
Q3 25
Q2 25
Q1 25
0.1%
Q4 24
0.2%
Q3 24
Q2 24
Q1 24
Q3 23
Cash Conversion
GAU
GAU
STOK
STOK
Q3 25
Q2 25
4.30×
Q1 25
1.17×
Q4 24
Q3 24
26.04×
Q2 24
1.05×
Q1 24
Q3 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons